Cargando…

Inhibition of Aβ(42) oligomerization in yeast by a PICALM ortholog and certain FDA approved drugs

The formation of small Aβ(42) oligomers has been implicated as a toxic species in Alzheimer disease (AD). In strong support of this hypothesis we found that overexpression of Yap1802, the yeast ortholog of the human AD risk factor, phosphatidylinositol binding clathrin assembly protein (PICALM), red...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Sei-Kyoung, Ratia, Kiira, Ba, Mariam, Valencik, Maria, Liebman, Susan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shared Science Publishers OG 2016
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349104/ https://www.ncbi.nlm.nih.gov/pubmed/28357335 http://dx.doi.org/10.15698/mic2016.02.476

Ejemplares similares

Development and validation of a yeast high-throughput screen for inhibitors of Aβ(42) oligomerization
por: Park, Sei-Kyoung, et al.
Publicado: (2011)

Yeast screening platform identifies FDA-approved drugs that reduce Aβ oligomerization
por: Amen, Triana, et al.
Publicado: (2016)

Modulation of Aβ(42 )low-n oligomerization using a novel yeast reporter system
por: Bagriantsev, Sviatoslav, et al.
Publicado: (2006)

An intronic PICALM polymorphism, rs588076, is associated with allelic expression of a PICALM isoform
por: Parikh, Ishita, et al.
Publicado: (2014)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Association of Alzheimer’s disease risk variants on the PICALM gene with PICALM expression, core biomarkers, and feature neurodegeneration
por: Xu, Wei, et al.
Publicado: (2020)

Genetics of PICALM Expression and Alzheimer's Disease
por: Parikh, Ishita, et al.
Publicado: (2014)

PICALM and Alzheimer’s Disease: An Update and Perspectives
por: Ando, Kunie, et al.
Publicado: (2022)

PICALM rescues glutamatergic neurotransmission, behavioural function and survival in a Drosophila model of Aβ42 toxicity
por: Yu, Yifan, et al.
Publicado: (2020)

A yeast model for amyloid-β aggregation exemplifies the role of membrane trafficking and PICALM in cytotoxicity
por: D’Angelo, Fabien, et al.
Publicado: (2013)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

PICALM modulates autophagy activity and tau accumulation
por: Moreau, Kevin, et al.
Publicado: (2014)

TDP-43 Toxicity in Yeast Is Associated with a Reduction in Autophagy, and Deletions of TIP41 and PBP1 Counteract These Effects
por: Park, Sei-Kyoung, et al.
Publicado: (2022)

PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid β42, and Phosphorylated Tau in the Elderly
por: Wu, Zhiwei, et al.
Publicado: (2022)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Corrigendum: PICALM modulates autophagy activity and tau accumulation
por: Moreau, Kevin, et al.
Publicado: (2015)

Modulation of PICALM Levels Perturbs Cellular Cholesterol Homeostasis
por: Mercer, Jacob L., et al.
Publicado: (2015)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

FDA efficiency for approval process of COVID-19 therapeutics
por: Cassidy, Christine, et al.
Publicado: (2020)

Coronavirus Papain-like Peptidases
por: Ratia, Kiira, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_u1ei7msr3m2fnud8c10m0d4qrt